Breadcrumb

James W. Hodge, Ph.D., MBA

James W. Hodge, Ph.D., M.B.A.

  • Center for Cancer Research
  • National Cancer Institute
Center for Immuno-Oncology

RESEARCH SUMMARY

Dr. Hodge is the Head of the Immunotherapeutics Section. This group investigates how combination immunotherapies and non-immune–based therapies affect tumor cells and specific components of the immune system. These studies form the rationale for novel immune- and non-immune-based combination clinical trials.

Dr. Hodge pioneered the development of vaccines and vaccine strategies for cancer immunotherapy including a) recombinant vectors to deliver tumor antigens, b) the use of costimulation to enhance antitumor T-cell responses, c) the combined use of vaccines with radiation, chemotherapy, and targeted small-molecule therapeutics. These concepts and therapeutics have been translated into many randomized multi-center trials at numerous Cancer Centers.

Areas of Expertise

1) immunotherapy 2) cancer vaccines 3) radiation 4) chemotherapy 5) combination therapies 6) cytotoxic T-cells (CTL)

Publications

Selected Key Publications

Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing

Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW.
Oncotarget. 5: 403-16, 2014. [ Journal Article ]

Tumor cells surviving exposure to proton or photon radiation share a common immunogenic modulation signature, rendering them more sensitive to T cell-mediated killing

Gameiro SR, Malamas AS, Bernstein MB, Tsang KY, Vassantachart A, Sahoo N, Tailor R, Pidikiti R, Guha CP, Hahn SM, Krishnan S, Hodge JW.
Int J Radiat Oncol Biol Phys. 95(1): 120-30, 2016. [ Journal Article ]

Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway

Ardiani A, Gameiro SR, Kwilas AR, Donahue RN, Hodge JW.
Oncotarget. 2(19): 9335-48, 2014. [ Journal Article ]

Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines

Farsaci B, Donahue RN, Coplin MA, Grenga I, Lepone LM, Molinolo AA, Hodge JW.
Cancer Immunol Res. 2(11): 1090-1102, 2014. [ Journal Article ]

Job Vacancies

There are no open positions at this time. Check back again later, or take a look at CCR's Careers page.

Team

Michelle Padget
Biologist
Michelle Padget
Sandy Reynolds
Postbaccalaureate
Sandy Reynolds
Ginette Santiago-Sanchez
Postdoctoral Fellow (CRTA)
Ginette Santiago Sanchez, PhD
David Zahavi
Post-doctoral Fellow (CRTA)
David J. Zahavi, Ph.D.